BPP Corporate Formation

CHARLOTTE, NC — Bright Path Pharmaceuticals, LLC (privately held), a developmental stage bio-pharmaceutical manufacturing company, is developing first-in-class continuous-flow technologies  solely focused on the production of active pharmaceutical ingredients (“API’s”), today announced that the North Carolina Secretary of State has approved its’ corporate formation.  The company founders, Anthony J. Quinones and John E. Allen Jr., have a long history in early stage corporate formation and commercialization of novel technologies.

Mr. Quinones, owner of the continuous-flow technology, stated. “I have known John Allen as a top pharma executive, who is able to create value for shareholders and commercialize novel technologies.  I am thrilled to have been able to recruit John as an inaugural founder of the company and he is a perfect fit for the company to help me lead the effort in the pharma space for this technology.”

About Bright Path Pharmaceuticals, LLC

Bright Path Pharmaceuticals, LLC is a developmental stage bio-pharmaceutical manufacturing company, dedicated to developing best-in-class continuous-flow manufacturing for the pharmaceutical sector.  For more information, please visit www.brightpathrx.com.

Safe Harbor

To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Bright Path Pharmaceuticals’ plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products, and development activities, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Bright Path Pharmaceuticals’ actual results to be materially different than those expressed in or implied by Bright Path Pharmaceuticals’ forward-looking statements. For Bright Path Pharmaceuticals, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the success and design of manufacturing facilities; and Bright Path Pharmaceuticals’ need for and ability to obtain additional financing. Bright Path Pharmaceuticals undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.